ATE535529T1 - Verfahren zur acylierung von maytansinol mit chiralen aminosäuren - Google Patents
Verfahren zur acylierung von maytansinol mit chiralen aminosäurenInfo
- Publication number
- ATE535529T1 ATE535529T1 AT06800952T AT06800952T ATE535529T1 AT E535529 T1 ATE535529 T1 AT E535529T1 AT 06800952 T AT06800952 T AT 06800952T AT 06800952 T AT06800952 T AT 06800952T AT E535529 T1 ATE535529 T1 AT E535529T1
- Authority
- AT
- Austria
- Prior art keywords
- maytansinol
- acylation
- amino acids
- chiral amino
- chiral
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 150000001413 amino acids Chemical class 0.000 title abstract 2
- QWPXBEHQFHACTK-RZKXNLMUSA-N CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](O)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](O)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-RZKXNLMUSA-N 0.000 title 1
- QWPXBEHQFHACTK-UHFFFAOYSA-N Maytansinol Natural products CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)C=CC=C(C)CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-UHFFFAOYSA-N 0.000 title 1
- 230000010933 acylation Effects 0.000 title 1
- 238000005917 acylation reaction Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000006345 epimerization reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70669405P | 2005-08-09 | 2005-08-09 | |
| PCT/US2006/030857 WO2007021674A2 (en) | 2005-08-09 | 2006-08-08 | Method of acylating maytansinol with chiral amino acids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE535529T1 true ATE535529T1 (de) | 2011-12-15 |
Family
ID=37758086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06800952T ATE535529T1 (de) | 2005-08-09 | 2006-08-08 | Verfahren zur acylierung von maytansinol mit chiralen aminosäuren |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7598375B2 (de) |
| EP (1) | EP1913002B9 (de) |
| JP (1) | JP5167130B2 (de) |
| AT (1) | ATE535529T1 (de) |
| AU (1) | AU2006280146B2 (de) |
| CA (1) | CA2617953C (de) |
| WO (1) | WO2007021674A2 (de) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| ATE446317T1 (de) | 2001-05-11 | 2009-11-15 | Ludwig Inst For Cancer Res Ltd | Spezifische bindungsproteine und ihre verwendung |
| CN101711284A (zh) * | 2007-01-25 | 2010-05-19 | 达娜-法勃肿瘤研究所 | 抗egfr抗体在治疗egfr突变体介导的疾病中的用途 |
| ES2542152T3 (es) * | 2007-03-15 | 2015-07-31 | Ludwig Institute For Cancer Research Ltd. | Método de tratamiento que emplea anticuerpos de EGFR e inhibidores de Src y formulaciones relacionadas |
| JP5469600B2 (ja) | 2007-07-16 | 2014-04-16 | ジェネンテック， インコーポレイテッド | 抗ＣＤ７９ｂ抗体及びイムノコンジュゲートとその使用方法 |
| SG183044A1 (en) | 2007-07-16 | 2012-08-30 | Genentech Inc | Humanized anti-cd79b antibodies and immunoconjugatesand methods of use |
| WO2009023265A1 (en) | 2007-08-14 | 2009-02-19 | Ludwig Institute For Cancer Research | Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof |
| UA106586C2 (uk) | 2008-01-31 | 2014-09-25 | Дженентек, Інк. | Анти-cd79b антитіла, і імунокон'югати та способи їх застосування |
| BRPI1012676A2 (pt) | 2009-04-01 | 2016-04-05 | Genentech Inc | anticorpos anti-fcrh5 e imunoconjugados e métodos de uso |
| US20110076232A1 (en) * | 2009-09-29 | 2011-03-31 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
| TW201117814A (en) | 2009-10-02 | 2011-06-01 | Sanofi Aventis | New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody |
| CA2816426A1 (en) | 2010-11-17 | 2012-06-07 | Genentech, Inc. | Alaninyl maytansinol antibody conjugates |
| RS58620B1 (sr) | 2011-02-15 | 2019-05-31 | Immunogen Inc | Metodi pripremanja konjugata |
| EA029797B1 (ru) | 2011-06-21 | 2018-05-31 | Иммуноджен, Инк. | Новые производные майтанзиноида с пептидным линкером и их конъюгаты |
| AP2014007588A0 (en) | 2011-09-22 | 2014-04-30 | Amgen Inc | CD27L antigen binding proteins |
| AR091069A1 (es) | 2012-05-18 | 2014-12-30 | Amgen Inc | Proteinas de union a antigeno dirigidas contra el receptor st2 |
| LT2900676T (lt) | 2012-09-26 | 2019-03-25 | Immunogen, Inc. | Maitanzinolio acilinimo patobulintas būdas |
| TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| CN103288957B (zh) | 2012-12-21 | 2015-01-28 | 百奥泰生物科技(广州)有限公司 | 一种抑制肿瘤生长的抗体药物衍生物及其制备方法和用途 |
| CN103254213B (zh) * | 2012-12-21 | 2015-02-25 | 百奥泰生物科技(广州)有限公司 | 类美登素酯的制备方法及用于所述方法的组合物 |
| ES2728936T3 (es) | 2013-01-25 | 2019-10-29 | Amgen Inc | Anticuerpos dirigidos contra CDH19 para melanoma |
| WO2014134483A2 (en) | 2013-02-28 | 2014-09-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| KR102306490B1 (ko) | 2013-03-15 | 2021-09-28 | 리제너론 파아마슈티컬스, 인크. | 생물학적 활성 분자, 그의 접합체 및 치료 용도 |
| EP3456743B1 (de) | 2013-05-30 | 2021-08-18 | Kiniksa Pharmaceuticals, Ltd. | Oncostatin-m-rezeptor-antigenbindende proteine |
| WO2014194030A2 (en) | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| TWI541022B (zh) | 2013-12-18 | 2016-07-11 | 應克隆公司 | 針對纖維母細胞生長因子受體－３（ｆｇｆｒ３）之化合物及治療方法 |
| CN105585579A (zh) * | 2014-10-24 | 2016-05-18 | 南京联宁生物制药有限公司 | 一种化合物及其制备方法以及美登素dm1的制备方法 |
| CN104623687B (zh) * | 2015-03-11 | 2017-09-05 | 中国科学院上海高等研究院 | 利用美登醇制备的抗体药物偶联物及其制备方法和应用 |
| AU2016233227B2 (en) | 2015-03-17 | 2020-03-12 | Regeneron Pharmaceuticals, Inc. | Amino acid acylation reagents and methods of using the same |
| SG11201707148PA (en) | 2015-03-27 | 2017-10-30 | Regeneron Pharma | Maytansinoid derivatives, conjugates thereof, and methods of use |
| TW201711702A (zh) | 2015-06-04 | 2017-04-01 | 應克隆公司 | 使用針對纖維母細胞生長因子受體３（ｆｇｆｒ３）之化合物的療法 |
| SI3956332T1 (sl) | 2019-04-18 | 2023-05-31 | Indena S.P.A. | Diasteroselektivni postopek za pripravo tiol- ali disulfid-vsebujočih majtansinoidnih estrov in njihovih intermediatov |
| AU2023341187A1 (en) * | 2022-09-16 | 2025-03-27 | Immunogen, Inc. | Improved methods for preparing n-methyl alanine esters of maytansinol |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4260609A (en) * | 1977-06-01 | 1981-04-07 | Merck & Co., Inc. | Di- and tri- substituted thiazoles |
| JPS5566585A (en) * | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164686A (en) * | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US5208020A (en) * | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2026147C (en) * | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US6333410B1 (en) * | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| WO2003074551A2 (en) * | 2002-03-01 | 2003-09-12 | The Administrators Of The Tulane Educational Fund | Conjugates of therapeutic or cytotoxic agents and biologically active peptides |
| US7301019B2 (en) * | 2005-01-21 | 2007-11-27 | Immunogen, Inc. | Method for the preparation of maytansinoid esters |
-
2006
- 2006-08-08 CA CA2617953A patent/CA2617953C/en active Active
- 2006-08-08 WO PCT/US2006/030857 patent/WO2007021674A2/en not_active Ceased
- 2006-08-08 AT AT06800952T patent/ATE535529T1/de active
- 2006-08-08 AU AU2006280146A patent/AU2006280146B2/en active Active
- 2006-08-08 US US11/500,378 patent/US7598375B2/en active Active
- 2006-08-08 JP JP2008526125A patent/JP5167130B2/ja active Active
- 2006-08-08 EP EP06800952A patent/EP1913002B9/de active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20070037972A1 (en) | 2007-02-15 |
| US7598375B2 (en) | 2009-10-06 |
| JP2009504655A (ja) | 2009-02-05 |
| EP1913002B9 (de) | 2012-04-25 |
| WO2007021674A2 (en) | 2007-02-22 |
| JP5167130B2 (ja) | 2013-03-21 |
| AU2006280146A1 (en) | 2007-02-22 |
| EP1913002A2 (de) | 2008-04-23 |
| CA2617953A1 (en) | 2007-02-22 |
| AU2006280146B2 (en) | 2012-06-28 |
| CA2617953C (en) | 2013-12-17 |
| EP1913002B1 (de) | 2011-11-30 |
| EP1913002A4 (de) | 2010-10-27 |
| WO2007021674A3 (en) | 2007-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE535529T1 (de) | Verfahren zur acylierung von maytansinol mit chiralen aminosäuren | |
| DE602005011656D1 (de) | Verfahren zur behandlung von dickdarmkrebs mit botulinum neurotoxin | |
| ATE475419T1 (de) | Verfahren zur zubereitung von lansoprazol | |
| DE602004032160D1 (de) | Verfahren zur Zubereitung von Getränken | |
| DE602004002519D1 (de) | Verfahren zur Oberflächenbehandlung von Metallen | |
| EP1912674B8 (de) | Bispezifische einzelketten-fv-antikörper-moleküle und anwendungsverfahren dafür | |
| DK1615952T3 (da) | Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler | |
| ATE464908T1 (de) | Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern | |
| DE602005016292D1 (de) | Verfahren zur herstellung von glatiramer | |
| DE60321130D1 (de) | Variation von parametern zur neurostimulation | |
| DE502004001613D1 (de) | Verfahren zur herstellung von polyamiden | |
| DE602005019144D1 (de) | Verfahren zur schmerzbehandlung in knochenkrebs du | |
| ATE482966T1 (de) | Verfahren zur herstellung von 7-alpha-alkylierte 19-norsteroide | |
| DE602004000313D1 (de) | Verfahren zur Verfügungstellung von ozonenthaltendem Wasser | |
| DE60325381D1 (de) | Proteine die cross-beta-struktur enthaltendes amyloid binden, sowie verfahren zur modulation der cross-beta-struktur, ihrer bildung und der damit zusammenhängenden toxizität | |
| DE602004020895D1 (de) | Verfahren zur herstellung von kohlenstoffnanospulen | |
| DE10390418D2 (de) | Verfahren zur Herstellung von rekombinanten Proteinen in Mikroorganismen | |
| DE502004005626D1 (de) | Verfahren zur herstellung von organoacylphosphiten | |
| EP1899472A4 (de) | Geänderter glyoxylat-shunt zur verbesserten produktion von aspartat abgeleiteter aminosäuren und chemikalien | |
| DE60331111D1 (de) | Verfahren zur Herstellung von martensitaushärtendem Stahl | |
| EP1888106A4 (de) | Zusammensetzungen und verfahren zur behandlung von ephrinsignalisierung mit cupredoxinen | |
| ATE456666T1 (de) | Verfahren zur auswertung von ribonukleotidsequenzen | |
| DE60325194D1 (de) | Methoden zur verwendung von lamellaren körpern für therapeutische zwecke | |
| WO2005009361A3 (en) | Method of treating hit patients with argatroban | |
| ATE440980T1 (de) | Verfahren zur hydrolyse von polyphosphorsäure in geformten artikeln |